The Food and Drug Administration gave InfraReDx Inc. 510(k) clearance for the company’s LipiScan IVUS coronary imaging system.
The device employs both so-called “near-infrared” spectroscopy and intravascular ultrasound technology to give cardiologists a grayscale IVUS image of a coronary artery, along with a map of lipid core coronary plaques within a blood vessel.
The data enables cardiologists to both visualize coronary plaques to guide stent placement and determine whether the build-ups are comprised of the fatty plaques that complicate stenting procedures and patients’ recovery, according to a press release.
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
The company said LipiScan IVUS is the first and only FDA cleared product to pair NIR spectroscopy and IVUS technology into one system.
Burlington, Massachusetts-based InfraReDx is planning its commercial launch of the imaging system in the U.S. later this year and is hoping for CE Mark approval in Europe in 2011. The company currently sells the LipiScan NIR system and the device is in use at approximately 25 cardiac centers in the U.S.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
Automation Didn’t Dehumanize Care. Bad Systems Did.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.